# A Study of LY2624587 in Patients With Advanced Cancer

> **NCT01139788** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 56 (estimated)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** LY2624587

## Key facts

- **NCT ID:** NCT01139788
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2012-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139788, "A Study of LY2624587 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01139788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*